Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms

Autor: Kanagal-Shamanna, Rashmi, Hodge, Jennelle C., Tucker, Tracy, Shetty, Shashi, Yenamandra, Ashwini, Dixon-McIver, Amanda, Bryke, Christine, Huxley, Emma, Lennon, Patrick A., Raca, Gordana, Xu, Xinjie, Jeffries, Sally, Quintero-Rivera, Fabiola, Greipp, Patricia T., Slovak, Marilyn L., Iqbal, M. Anwar, Fang, Min
Zdroj: In Cancer Genetics December 2018 228-229:197-217
Databáze: ScienceDirect
Externí odkaz: